PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
118.91%
Cash & equivalents yoy growth at least 1.5x AXSM's 0.70%. Mohnish Pabrai might see this as a favorable liquidity edge, provided funds are well deployed.
No Data
No Data available this quarter, please select a different quarter.
118.91%
Cash + STI yoy ≥ 1.5x AXSM's 0.70%. David Dodd might see it as a strategic cash buffer advantage. Evaluate deployment plans.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
104.59%
≥ 1.5x AXSM's 8.49%. David Dodd might see a short-term liquidity advantage or potential underutilized capital.
15.06%
Below half AXSM's -3.53%. Michael Burry sees potential underinvestment risk unless there's a valid reason (asset-light model).
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-15.06%
Less than half of AXSM's 16.55%. David Dodd sees fewer expansions in non-core assets. Possibly a simpler focus.
15.06%
≥ 1.5x AXSM's 1.11%. David Dodd sees significantly higher long-term asset buildup. Confirm synergy with strategy.
No Data
No Data available this quarter, please select a different quarter.
104.51%
≥ 1.5x AXSM's 7.23%. David Dodd notes a larger balance sheet expansion. Confirm it's not overleveraged.
55.57%
Above 1.5x AXSM's 6.97%. Michael Burry questions if payables are being stretched to avoid short-term borrowing.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
719.98%
Exceeding 1.5x AXSM's 14.15%. Michael Burry suspects ballooning short-term obligations vs. competitor.
14812.60%
Above 1.5x AXSM's 40.25%. Michael Burry sees a red flag for liquidity risk vs. competitor.
-100.00%
Above 1.5x AXSM's -30.63%. Michael Burry suspects significant leverage additions. Check coverage.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Above 1.5x AXSM's -25.02%. Michael Burry sees a strong spike vs. competitor. Check coverage and debt ratios.
No Data
No Data available this quarter, please select a different quarter.
4364.90%
Above 1.5x AXSM's 4.28%. Michael Burry sees a potential leverage warning sign.
91.77%
Higher Common Stock (Book Value) Growth compared to AXSM's zero value, indicating worse performance.
-19849.13%
≥ 1.5x AXSM's -4.06%. David Dodd sees higher yoy retained profits than competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
1201.65%
≥ 1.5x AXSM's 37.35%. David Dodd sees stronger capital base growth than competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
92.16%
Above 1.5x AXSM's 2.81%. Michael Burry sees a major jump. Investigate leverage rationale.
-119.69%
Less than half of AXSM's 4.12%. David Dodd sees better deleveraging or stronger cash buildup than competitor.